EXHIBIT 99.1

Investor Contacts:
Elizabeth Foster or Claudia Jones of Neurocrine Biosciences
(858) 617-7600

             NEUROCRINE ANNOUNCES ACCEPTANCE OF NEW DRUG APPLICATION
                              FOR INDIPLON CAPSULES

San Diego, CA, June 14, 2005 - Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
announced today that the U.S. Food and Drug Administration (FDA) has accepted
the Company's New Drug Application (NDA) for indiplon capsules for review for
the treatment of insomnia in both adult and elderly patients.

Indiplon is a unique non-narcotic, non-benzodiazapine agent that acts on a
specific site of the GABA-A receptor. Indiplon has been shown to bind
selectively to the specific subtype of GABA-A receptors within the brain
believed to be responsible for promoting sleep. Indiplon was developed to
address different types of sleep problems. Indiplon was licensed from DOV
Pharmaceutical in 1998.

Insomnia is a prevalent condition in the United States. According to the
National Sleep Foundation's (NSF) Sleep in America Poll 2005 approximately half
of America's adults report that they experienced at least one symptom of
insomnia a few nights a week or more in the past year. Sleep loss has been found
to impair the ability to perform tasks involving memory, learning, and logical
reasoning, yet few people understand the importance of sufficient sleep.

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company
focused on neurological and endocrine diseases and disorders. Our product
candidates address some of the largest pharmaceutical markets in the world
including insomnia, anxiety, depression, diabetes, multiple sclerosis, irritable
bowel syndrome, eating disorders, pain, and autoimmunity. Neurocrine
Biosciences, Inc. news releases are available through the Company's website via
the Internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain forward-looking
statements that involve a number of risks and uncertainties. Among the factors
that could cause actual results to differ materially from those indicated in the
forward-looking statements are risks and uncertainties associated with
Neurocrine's business and finances in general including, but not limited to,
risk and uncertainties associated with the Company's indiplon program and
planned regulatory activities including, but not limited to; risk that
regulatory authorities find our regulatory submissions incomplete or
insufficient or otherwise unapprovable; and the other risks described in the
Company's report on Form 10-K for the year ended December 31, 2004 and report on
Form 10-Q for the quarter ended March 31, 2005. Neurocrine undertakes no
obligation to update the statements contained in this press release after the
date hereof.


                                       ###